Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hari Krishna Ananthula

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The AAPS Journal|May 4, 2010
Ocular drug deliveryRipal Gaudana, Hari Krishna Ananthula, Ashwin Parenky, et al.
International Journal of Pharmaceutics|September 29, 2009
Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3)Durga Kalyani Paturi, Deep Kwatra, Hari Krishna Ananthula, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2023
Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixantAkshita Chawla, Anna Largajolli, Azher Hussain, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2018
Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal SphingolipidsCristina Lazzarini, Krupanandan Haranahalli, Robert Rieger, et al.
BMC Pharmacology & Toxicology|December 6, 2018
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agentsHari Krishna Ananthula, Scott Parker, Erin Touchette, et al.
Mbio|June 25, 2015
Identification of a New Class of Antifungals Targeting the Synthesis of Fungal SphingolipidsVisesato Mor, Antonella Rella, Amir M Farnoud, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The AAPS Journal|May 4, 2010
Ocular drug deliveryRipal Gaudana, Hari Krishna Ananthula, Ashwin Parenky, et al.
International Journal of Pharmaceutics|September 29, 2009
Identification and functional characterization of breast cancer resistance protein in human bronchial epithelial cells (Calu-3)Durga Kalyani Paturi, Deep Kwatra, Hari Krishna Ananthula, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 6, 2023
Population pharmacokinetic analysis of the P2X3-receptor antagonist gefapixantAkshita Chawla, Anna Largajolli, Azher Hussain, et al.
Antimicrobial Agents and Chemotherapy|March 7, 2018
Acylhydrazones as Antifungal Agents Targeting the Synthesis of Fungal SphingolipidsCristina Lazzarini, Krupanandan Haranahalli, Robert Rieger, et al.
BMC Pharmacology & Toxicology|December 6, 2018
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agentsHari Krishna Ananthula, Scott Parker, Erin Touchette, et al.
Mbio|June 25, 2015
Identification of a New Class of Antifungals Targeting the Synthesis of Fungal SphingolipidsVisesato Mor, Antonella Rella, Amir M Farnoud, et al.
Pageof 1